Stanford, CA, United States of America

David Bram Lewis

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2011-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: David Bram Lewis: Innovator in Therapeutic Alloantigen-Specific Regulatory T Cells

Introduction

David Bram Lewis is a notable inventor based in Stanford, CA (US). He has made significant contributions to the field of immunology, particularly in the development of methods for inducing and expanding therapeutic alloantigen-specific human regulatory T cells. With a total of 3 patents, his work has the potential to impact therapeutic strategies for various diseases.

Latest Patents

Lewis's latest patents focus on innovative methods for inducing, expanding, and generating alloantigen-specific regulatory T cells. These regulatory T cells can be derived from naive CD4CD25T cells using CD40-activated B cells. His work emphasizes the generation of human T cells, specifically CD4CD25Foxp3 regulatory T cells, which are crucial for therapeutic applications.

Career Highlights

Throughout his career, David Bram Lewis has been associated with prestigious institutions such as Leland Stanford Junior University and Versitech, Inc. His research has contributed to advancements in the understanding and application of regulatory T cells in therapeutic settings.

Collaborations

Lewis has collaborated with notable colleagues, including Wenwei Tu and Yu-Lung Lau. These partnerships have further enriched his research and development efforts in the field of immunology.

Conclusion

David Bram Lewis stands out as an influential inventor in the realm of therapeutic alloantigen-specific regulatory T cells. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…